Benralizumab (Fasenra) is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1, kappa) indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
Benralizumab (Fasenra) is not indicated for treatment of other eosinophilic conditions and not indicated for the relief of acute bronchospasm or status asthmaticus.
Everyone has eosinophils (e-o-SIN-o-phils). They’re white blood cells, a normal part of your immune system. Nearly 7 out of 10 adults with asthma may have elevated eosinophils.† Too many eosinophils can cause airway inflammation for some people, which can lead to asthma symptoms and attacks.
Benralizumab (Fasenra) is designed to target and remove eosinophils.
Benralizumab (Fasenra) injection is a sterile, preservative-free, clear to opalescent, colorless to slightly yellow solution and may contain a few translucent or white to off-white particles, for subcutaneous injection supplied as a single-dose prefilled syringe or single-dose autoinjector.
The recommended dose of Benralizumab (Fasenra) is 30 mg administered once every 4 weeks for the first 3 doses, and then once every 8 weeks thereafter by subcutaneous injection into the upper arm, thigh, or abdomen.
